|Over a month ago|
Tactile Systems sees FY20 revenue $227.5M- $230.5M, consensus $224.83M » 16:2302/2602/26/20
The Company expects full…
The Company expects full year 2020 total revenue in the range of $227.5 million to $230.5 million, representing growth of 20% to 22% year-over-year, compared to total revenue of $189.5 million in 2019.
Tactile Systems reports Q4 EPS 22c, consensus 25c » 16:2202/2602/26/20
Reports Q4 revenue…
Reports Q4 revenue $57.1M, consensus $55.52M. "We are pleased to report another quarter of impressive performance, which resulted in revenue growth of 23% year-over-year," said Gerald R. Mattys, Chief Executive Officer of Tactile Medical. "Our solid execution during the fourth quarter enabled us to bring 2019 to a strong close, with improved profitability and full year revenue growth of 32%. Our success was driven by investments in expanding our field sales team, solid market adoption of the Flexitouch Plus system, a targeting strategy focused on the most productive accounts in the lymphedema market and the broad in-network coverage we have obtained with commercial payers. As we enter 2020, we remain focused on increasing our share of the growing $5+ billion addressable U.S. market opportunity in lymphedema and chronic venous insufficiency and believe we are poised to deliver 20% or more top line growth and another year of improved profitability."
Tactile Systems announces denial of motion to dismiss qui tam complaint » 07:3402/2402/24/20
Tactile Systems Technology announced that the Company's motion to dismiss the qui tam complaint filed against the Company has been denied by the court. "We are disappointed that our motion to dismiss was denied and we will continue to defend ourselves against these allegations as the litigation moves forward," said Gerald R. Mattys, Chief Executive Officer of Tactile Medical. "The judge's decision was in no way an indication of wrongdoing on our behalf, or a validation of the merits of the allegations; it merely represents a determination that there was sufficient information in the complaint to move to the next step in the process. We are now working expeditiously to respond to the complaint formally and will continue to update the investment community of material developments in the litigation process going forward."
Lawsuit may drag out into 2021, impact on Tactile 'modest,' says Piper Sandler » 16:5501/2001/20/20
Piper Sandler analyst…
Piper Sandler analyst Matt O'Brien notes that a scheduling order in the qui tam litigation was issued that could see the lawsuit drag out into 2021. The analyst believes most investors had expected that the litigation would be completed this year, so this uncertainty is likely being viewed negatively. O'Brien understands that this is disappointing but believes the financial impact on the company will be "modest and manageable." Consequently, he encourages investors to take advantage of the recent stock weakness. The analyst reiterates an Overweight rating and a $70 price target on the shares.
Tactile Systems momentum to benefit further results, says Piper Sandler » 19:4801/1301/13/20
Piper Sandler analyst…
Piper Sandler analyst Matt O'Brien keeps his Overweight rating and $70 price target on Tactile Systems after the company pre-announced its Q4 revenue and guided FY20 ahead of consensus estimates, with the beat coming from its product segments and new product launches. The analyst expects the momentum to continue as Tactile Systems rolls out head and neck offerings, with added opportunity coming from its early stage of penetration into the lymphedema market.
Tactile Systems CEO Gerald Mattys to retire » 07:2601/1301/13/20
Tactile Systems announced…
Tactile Systems announced that Gerald R. Mattys has communicated his intention to retire as Chief Executive Officer of the Company in 2020. The Board of Directors has initiated a process to identify a successor for Mr. Mattys and has engaged an executive search firm to support the search. Mr. Mattys plans to continue as the Chief Executive Officer until his successor has started and will assist in ensuring a successful transition.
Tactile Systems sees FY20 revenue $227.5M-$230.5M, consensus $223.16M » 07:2501/1301/13/20
"We are pleased to…
"We are pleased to report impressive performance during the fourth quarter, which resulted in expected revenue growth of 21% to 22% year-over-year," said Gerald R. Mattys, Chief Executive Officer of Tactile Medical. "Our solid execution during the fourth quarter enabled us to bring 2019 to a strong close, with improved profitability and expected full year 2019 revenue growth of approximately 31% driven by investments in the field sales team, solid market adoption of the Flexitouch Plus system, a targeting strategy focused on the most productive accounts in the lymphedema market and the broad in-network coverage we have obtained with commercial payers. As we enter 2020, we remain focused on expanding our share of the $4+ billion U.S. market in lymphedema and chronic venous insufficiency and believe we are poised to deliver another year of 20% plus revenue growth and improved profitability."
Tactile Systems sees FY19 revenue $188.4M-$188.8M, consensus $187.21M 07:2401/1301/13/20
Tactile Systems sees Q4 revenue $56M-$56.4M, consensus $53.86M 07:2301/1301/13/20
|Over a quarter ago|
Tactile Systems management to meet with BTIG » 04:5512/1912/19/19
Meetings to be held in…
Meetings to be held in Texas on December 18-19 hosted by BTIG.